Abstract 2760
Background
TMB is an emerging biomarker for immune-therapy including metastasized UBC. The evaluation of reliable methods to determine the TMB value is a prerequisite for successful application of IO therapies.
Methods
TMB was assessed in genomic DNA from 39 muscle-invasive UBC by whole genome sequencing (GPS Cancer©, NantHealth). In 45 cases sequencing with the TruSight Oncology 500, (TSO500, Illumina) was performed. Immune cell (IC) infiltrates were analyzed by CD3, CD8, CD56, PD-1 and CD68 immunohistochemistry. PD-L1 status was evaluated by the SP263 assay (Ventana). Intrinsic subtypes (MDACC-approach) were assessed via a Nanostring-assay. Immune phenotypes were assessed by (I) spatial distribution of IC and (II) a T-cell inflammation related gene expression signature consisting of 29 genes (Nanostring). Results were validated in the TCGA MIBC cohort.
Results
Correlation between TSO500 and WGS revealed high concordance (spearman-correlation: r = 0.68, p < 0.0001). Overall percentage agreement was 76.9% for a cut-off of 10 mut/mb and 84.6% for 15 mut/mb. We found no significant association of high TMB at different cut-offs (10 mut/mb, 15 mut/mb) with inflammation status and different immune cell populations in both cohorts. TMB was not associated with intrinsic subtypes. Spatially distributed IC phenotypes or PD-L1 status was not associated with TMB. Hierarchical clustering of all factors revealed four distinct subgroups: Cluster A Inflamed, PD-L1 “high”, TMB high (n = 5); Cluster B Inflamed, PD-L1 “high”, TMB low-intermediate (n = 14); Cluster C: Uninflamed, PD-L1 “low”, TMB intermediate-high (n = 14); Cluster D Uninflamed, PD-L1 “low”, TMB low (n = 12).
Conclusions
This study provides insights into the reliability of a NGS panel for the prediction of TMB in MIBC which shows comparable performance to WGS. High TMB seems to be a characteristic of MIBC which occurs regardless of PD-L1 and inflammation status. TMB could possibly identify additional patients who do not fulfill the PD-L1 assessment based criteria for checkpoint inhibition.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Illumina, California, United States of America NantHealth, Culver City, California, United States of America.
Disclosure
M. Eckstein: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Janssen-Cilag. All other authors have declared no conflicts of interest.
Resources from the same session
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract